Deutsch English
← back to archive
Industry & Engineering · 592 words · MN-260623-0085

Chinese artificial heart enters global markets

MuckyNews reading

A metal pump the size of a ping-pong ball that levitates magnetically and simulates billions of heartbeats – that's BrioVAD. A Chinese-developed artificial heart currently making its international debut. In early June, the device was implanted in a patient at a Dutch hospital, after already securing approval for clinical trials in the US. By now, over three-quarters of the top 30 American hospitals for this type of procedure have joined the trial program.

This is more than just a neat medical milestone. There's a strategic pivot behind it, backed by the state. Developer Chen Chen initially built a magnetic predecessor in the US, which ultimately flopped commercially due to size and implantation issues. When investors pulled out, he went to Suzhou. Instead of following the global standard of hydrodynamic suspension, he pushed for the riskier leap to full magnetic levitation. A plan he pitched at a Ministry of Science and Technology meeting in Beijing in 2009 – and which clearly found state backing. The collaboration between ministries, universities, and industry paid off: the device has been in use since 2017 and is now implanted in over 1,000 patients.

It's quite remarkable that Chinese high-tech is making its first real inroads into Western top-tier hospitals in medical devices, rather than consumer electronics. The demand is enormous: in China alone, over a million end-stage heart failure patients face a meager 1,000 transplants a year. The artificial heart isn't a luxury; it's a desperate necessity. If Western clinical trials continue to go well, China is carving out market share in a field previously dominated by Western manufacturers. It's proof that state-coordinated tech development can deliver results without relying on the classic Silicon Valley venture-capital playbook.

Short version

  • The Chinese artificial heart BrioVAD was implanted for the first time in

Europe (Netherlands) in early June and is currently in US clinical trials.

  • Developer Chen Chen moved to China after US investors pulled out,

shifting focus to magnetic levitation over hydrodynamics and securing state backing.

  • The technology has been used in over 1,000 patients so far.
  • Global demand for artificial hearts is massive, given the severe

shortage of donor organs.

  • Pressure point: China is establishing a foothold in Western, highly

regulated medical high-tech markets through state-industrial coordination.

Perspective delta

  • **chinese_state**: The report is overwhelmingly framed as a success

story of state-directed innovation. It reads like a well-orchestrated narrative of government, academia, and industry working in perfect sync. The pivot from hydrodynamic suspension to magnetic levitation is presented as a bold, visionary move. The earlier commercial failure in the US is acknowledged, but smoothly reframed as a stepping stone. The massive domestic need – millions of patients, very few transplants – serves to legitimize state intervention. What's missing: any critical voices, development setbacks, or independent medical assessments. It's classic progress-driven PR.

Source base / limits

The source base is extremely narrow. The entire article rests on a single piece from People's Daily (PDY). It offers a strictly Chinese state perspective, lacking any independent medical analysis, outside commentary, or Western reporting. The claims regarding FDA approvals and implantation numbers seem plausible but are entirely one-sided. The story is clearly designed for narrative impact and lacks independent verification.

Sources / basis

  • MuckyNews container ID: MN-20260623-085
  • Source outlets/stations: Peoples Daily (PDY)
  • Perspective groups present: chinese_state
  • Article count: 1
  • Source count: 1
  • Perspective count: 1
  • Approximate raw text size: 3703 chars